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Mass spectrometric monitoring of albumin in uremia. disease and other disorders [1]. Successful kidney trans-
Background. Advanced glycation end products (AGEs) are plantation decreases the concentrations of uremic toxins,
a novel class of uremic toxins. In plasma, they are present
whereas dialysis is generally less effective. Few uremicin proteins and also in low molecular mass peptides. AGE-
toxins have been identified: They include parathyroid hor-modified peptides are thought to bind and modify plasma pro-
teins. Monitoring of the consequent increase in molecular mass mone, b2-microglobulin, indoxyl sulfate, potassium, inor-
of serum albumin may be used in surveillance of the clinical ganic phosphate, and hydrogen ions [1]. Recently, a fur-
management of uremia.
ther class of compounds, advanced glycation end productsMethods. We investigated molecular mass changes of human
(AGEs), have been proposed as uremic toxins [2–5].serum albumin (HSA) glycated by glucose and methylglyoxal
in vitro and of subjects with moderate renal impairment, end- Advanced glycation end products are terminal end-stage
stage renal disease (ESRD), ESRD on hemodialysis, and nor- adducts of protein glycation. Glycation of proteins occurs
mal healthy controls by matrix-assisted laser desorption ioniza-
by the nonenzymatic reaction of saccharide derivativestion mass spectrometry.
with proteins. Glucose and the physiological a-oxoalde-Results. Fatty acid-free HSA had a molecular mass of
66,446 6 114 D. Mean (6SD) molecular mass increases were hydes glyoxal, methylglyoxal and 3-deoxyglucosone are
HSA minimally glycated by glucose 399 6 88 D (N 5 5, P , particularly important glycating agents in vivo [6]. Lysine,
0.001), HSA highly glycated by glucose 6780 6 122 D (N 5 5,
arginine, and N-terminal amino acid residues are the ma-P , 0.001), HSA minimally glycated by methylglyoxal 73 6
jor amino acid residues modified. Glucose reacts initially121 D (N 5 5, P . 0.05), and HSA without fatty acid removal
535 6 90 D (N 5 5, P , 0.001). For HSA of human subjects, with N-terminal and lysine residues to form a Schiff’s base
mean (6 SD) molecular mass increases were normal healthy adduct [7] that undergoes an Amadori rearrangement to
controls 243 6 97 D (N 5 5), moderate renal impairment 350 6
form a fructosamine [8]. Glucose-modified proteins react83 D (P . 0.05 with respect to controls, N 5 5), ESRD 498 6
further to form AGEs [9]; a-oxoaldehydes also react128 (P , 0.02 with respect to controls, N 5 3), and ESRD on
hemodialysis 438 6 85 D (P , 0.02 with respect to controls, with proteins to form AGEs [6]. Examples of AGEs are:
N 5 5). The mean molecular mass of albumin of all groups Ne -carboxymethyl-lysine (CML), Ne -carboxyethyl-lysine,was increased significantly with respect to that of fatty acid
pyrraline, hydroimidazolones, argpyrimidine, bis(lysyl)free albumin (P , 0.001).
Conclusions. Only ESRD was associated with a significant imidazolium cross-links, and pentosidine [reviewed in
increase in the molecular mass of HSA in vivo. Since this mass 10]. Plasma protein content of pentosidine [2], CML [11],
increase was very low and much lower than reported for AGE- bis(lysyl)imidazolium cross-links derived from glyoxalmodified peptides, it may reflect AGE formation on HSA by
and methylglyoxal (GOLD and MOLD, respectively)a-oxoaldehydes that accumulate in uremia, rather than modi-
fication of albumin by AGE-modified peptides. The molecular [12], and other AGEs [13, 14] were increased in uremia.
mass of HSA in vivo was indicative of a minimal and not a Most AGEs determined by immunoassay with poly-
high extent of glycation.
clonal antibodies raised to proteins highly modified by
glucose-derived AGEs were low molecular mass pep-
tides (1,500 to 2000 D) and were called AGE peptidesThe accumulation of uremic toxins in chronic renal fail-
[13, 14]. Although antibodies raised to similar immuno-ure is associated with the development of cardiovascular
gens are now thought to detect mainly CML [15], the
AGEs detected in AGE peptides were probably notKey words: glycation, serum albumin, advanced glycation end prod-
ucts, end-stage renal disease, chronic renal failure, protein glycation. CML because .95% of CML in uremic patients was
associated with albumin [16]. AGE accumulation may
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and the accumulation of AGEs in uremia was associated (mean 11 years) previously. Three patients (two male;
with monocyte activation [18]. mean age of 49 years, range 45 to 53) with a serum
Novel analytical techniques that aid the characteriza- creatinine of 569 to 902 (mean 726) mmol/L had end-
tion and clinical control of AGEs may provide a valuable stage renal failure and were about to commence dialysis.
adjunct to patient support in surveillance of uremic tox- The causes of renal disease were polycystic kidney dis-
ins. The modification of albumin with AGEs will increase ease (1 patient), focal sclerosing glomerulosclerosis (1
its molecular mass. AGE peptides were found to react patient), and unknown (1 patient). The diagnosis had
with serum proteins in uremia [19, 20] that will therefore been made 2 to 10 years (mean 6 years) previously. Five
also give rise to increased molecular mass of albumin. patients (all male, mean age of 38 years, range 29 to 49)
Matrix-assisted laser desorption ionization mass spec- were on maintenance hemodialysis with a predialysis
trometry (MALDI-MS) was used to determine the mo- serum creatinine of 917 to 1412 (mean 1201) mmol/L.
lecular mass of human serum albumin (HSA) in the The causes of renal disease were reflux nephropathy (1
plasma of diabetic patients and normal controls [21, 22]. patient), focal sclerosing glomerulosclerosis (1 patient),
Increases in molecular mass were attributed to glycation. IgA nephropathy (1 patient), renal cell carcinoma (1
This report describes a similar investigation of molecu- patient), and unknown (1 patient). The diagnosis had
lar mass changes of HSA during glycation in vitro and been made 3 to 10 years (mean 6 years) previously.
in vivo. Molecular mass changes of HSA following glyca- Patients had reached end-stage renal failure between 1
tion by glucose and methylglyoxal in vitro under condi- and 10 years (mean 4.6 years) prior to study. All patients
tions typically used to prepare AGE-modified proteins used a bicarbonate dialysate and biocompatible hollow
for receptor binding and functional activity studies are fiber dialyzer (Hemophan; Gambro AB, Stockholm,
presented. A comparison is made of these with molecular Sweden) combining conventional hemodialysis and he-
mass changes of HSA from nondiabetic patients with mofiltration with volumetric fluid removal. Patients dia-
moderate renal impairment and with end-stage renal lyzed for an average of 11.2 h/week (range 9 to 12). Five
disease (ESRD) with and without treatment by hemodi- healthy control subjects (four male, mean age of 38 years,
alysis, and normal healthy control human subjects. We range 31 to 47) were recruited from volunteer medical
found modest but significant changes in molecular mass school and hospital staff and had normal renal function
of HSA of patients with ESRD with and without treat- with a serum creatinine of 91 to 112 (mean 106) mmol/L.
ment by hemodialysis, but not with moderate renal im- Venous whole blood samples were collected from the
pairment, relative to normal control subjects. From all antecubital vein into Vacutainer tubes (Becton Dickin-
subjects, the mean molecular mass of HSA was increased son, Oxford, UK) containing heparin. Samples from pa-
from that of fatty acid-free HSA. Similar mass changes
tients on hemodialysis were collected immediately be-
were found in HSA glycated minimally by glucose in
fore a dialysis session. The blood was centrifuged atvitro, but HSA highly glycated by glucose in vitro had
3000 3 g for 15 minutes, the plasma was separated anda molecular mass that was much higher than that of HSA
stored in liquid nitrogen until analysis.in physiological samples.
Preparation of glycated HSA in vitro
METHODS Human serum albumin highly modified by AGE
(AGE-HSA) was prepared by incubation of HSA (50Materials
mg/mL) with 1.67 mol/L glucose in 100 mmol/L sodiumHuman serum albumin preparations, fraction V 96 to
phosphate buffer, pH 7.4, at 378C, under aseptic condi-99% and fatty-acid free, and b-d-glucose were purchased
tions for 60 days, with a control incubation without glu-from Sigma (Poole, Dorset, UK). Methylglyoxal was pre-
cose for comparison [24]. AGE-HSA and control incu-pared and purified as described [23].
bated HSA were analyzed by MALDI-MS at 15-day
intervals. HSA minimally modified by glucose-derivedSubjects
AGE (AGEmin-HSA) was prepared by incubation ofControl subjects and patients were nondiabetic Euro-
HSA (50 mg/mL) in 150 mmol/L sodium phosphatepean Caucasians. Patients with renal failure were re-
buffer, pH 7.4, at 378C, with 50 mmol/L glucose for fivecruited from the nephrology and hemodialysis clinics at
weeks under aseptic conditions. HSA minimally modi-St. Bartholomew’s Hospital (London, UK). Five patients
fied by methylglyoxal (MGmin-HSA) was prepared by(four male; mean age of 41 years, range 35 to 46) with
incubation of the HSA (6.6 mg/mL) with 500 mmol/La serum creatinine of 183 to 366 (mean 276) mmol/L
methylglyoxal in 100 mmol/L sodium phosphate buffer,were designated as having moderate renal impairment.
pH 7.4, at 378C, under aseptic conditions for 24 hoursThe causes of renal disease were IgA nephropathy (3
[25]. After incubation, the proteins were dialyzed againstpatients), renal stone disease (1 patient), and unknown
(1 patient). The diagnosis had been made 2 to 14 years ammonium bicarbonate buffer (30 mmol/L, pH 7.9, at
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48C), lyophilized to dryness, and stored desiccated at mass ,66,600 to 66,950 D) of albumin. There was no
2208C. significant broadening of the molecular ion peak shapes
in subjects with moderate renal impairment and ESRD,
Sample preparation for MALDI-MS relative to normal controls. Rather, the mean molecular
Aliquots of plasma (20 mL) containing 50 to 70 mg/mL mass was increased (Fig. 1 A–C). When plasma protein
of protein were diluted to 400 mL with deionized water samples from a normal control and ESRD subjects were
and centrifuged in VectraSpin microtubes (12,000 D cut- mixed, however, the peaks of two molecular ions were
off membrane) at 8000 3 g for 20 minutes to a volume observed (Fig. 1D).
of 10 to 20 mL. This washing was repeated twice, and We investigated molecular mass changes of HSA of
then the samples were finally diluted to 1 mL with dis- subjects with moderate renal impairment, with ESRD,
tilled water. A 20 mL aliquot then was taken for MALDI- with ESRD on hemodialysis, and of normal healthy con-
MS analysis. Fatty acid-free albumin was prepared from trols by MALDI-MS. Fatty acid-free HSA was used as
the remainder of the final protein solution by titration the calibration and reference standard. Mean 6 SD mo-
to pH 3.0 with 0.1 mol/L HCl (approximately 7.5 mL), lecular mass increases were as follows: normal, healthy
addition of 1 mg of activated carbon and shaking of the controls 243 6 97 D (N 5 5); moderate renal impairment
sample for one hour at room temperature [26]. Then the 350 6 83 D (N 5 5), which was not increased significantly
samples were spin filtered (0.2 mm; 3000 3 g, 5 min), with respect to controls (P . 0.05); ESRD 498 6 128
and the clear filtrate was neutralized to pH 5.5 to 6.0 (N 5 3), which was increased significantly with respect
with 0.1 mol/L NaOH and analyzed by MALDI-MS. The to controls (P , 0.02); and ESRD on hemodialysis 438 6
analyses were performed in a Kratos Kompact MALDI 85 D (N 5 5), which was increased significantly with
II mass spectrometer, equipped with a nitrogen laser respect to controls (P , 0.02). Fatty acid-free HSA had
(337 nm), operating in positive high energy linear mode. a molecular mass of 66,446 6 114 D. The mean molecular
Laser power was tuned for proteins in the range of 20,000 mass of HSA of all groups was increased significantly
to 100,000 D. Instrument operation, data collection, and with respect to that of fatty acid-free HSA (P , 0.001;
analysis were made in a SunSparke workstation running Table 1). Processing of HSA samples of normal healthy
Kratos TofWaree. Matrix solution contained 10 mg/mL controls to remove fatty acids decreased the molecular
3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid) mass of HSA to 66,470 6 8 (N 5 3), which was not
in 60% vol/vol acetonitrile in 0.1% vol/vol aqueous tri- significantly different from the molecular mass of fatty
fluoroacetic acid. Sample protein solutions (1 mL of a acid free HSA (P . 0.05).
1:1 vol/vol mixture of 1 mg/mL total protein and matrix
solution) were applied on a sample spot in a steel plate Molecular mass of HSA glycated in vitro
slide and dried in a stream of warm air. Fatty acid free
MALDI-MS of glycated HSA derivatives prepared inHSA (66,446 D) was used as an external standard for
vitro gave two peaks with mass/charge ratios identifiablecalibration. Each spectrum represents data collected and
as the double-charged and mono-charged molecular ionsaveraged from 50 to 100 shots. Replicate sample prepara-
(Fig. 2). HSA minimally glycated by methylglyoxaltions were made for each sample (plasma, N 5 8 to 16;
(MGmin-HSA) had a molecular mass of 66,519 6 121 Dfatty acid free HSA, N 5 15). Samples were processed
(N 5 5), a mass increase of 73 D with respect to fattyin a blinded fashion.
acid-free HSA (P . 0.05). HSA without fatty acid re-Protein concentration was determined by the Coomas-
moval gave a molecular mass of 66,981 6 90 D (N 5 5),sie Brilliant Blue dye-binding assay, using HSA as stan-
a mass increase of 535 D with respect to fatty acid-freedard [27].
HSA (P , 0.001). HSA minimally glycated by glucose
(AGEmin-HSA) had a molecular mass of 66,845 6 88 DStatistical analysis
(N 5 5), a mass increase of 399 D with respect to fattySignificance of differences between sample mean mo-
acid-free HSA (P , 0.001). HSA highly glycated by glu-lecular mass values of albumin was assessed by Student’s
cose had a molecular mass of 73,226 6 122 D (N 5 5),t-test.
a mass increase of 6780 D with respect to fatty acid-free
HSA (P , 0.001). The time course of the molecular mass
RESULTS changes during the formation of AGE-HSA showed a
Molecular mass of HSA in vivo rapid increase in the initial 15 days of approximately
260 D per day, followed by a progressively slower in-MALDI-MS of high molecular serum protein samples
crease in mass to only approximately 58 D per day from(molecular mass .20,000 D) gave mass spectra with two
45 to 60 days (Fig. 3). HSA incubated without glucosepeaks of mass/charge ratios identifiable as the double-
under the same conditions showed no significant changecharged molecular ion (molecular mass ,33,300 to
33,475 D) and monocharged molecular ion (molecular in mass (P . 0.05).
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Fig. 1. Matrix assisted laser desorption ion-
ization-mass spectrometry (MALDI-MS) of
human serum albumin in uremia (typical). (A)
Normal control. (B) Moderate renal impair-
ment. (C) ESRD. (D) Normal control and
ESRD sample.
Table 1. Molecular mass of human serum albumin in uremia
Mass increment D with P value with respect to HSA (with
Molecular mass D respect to HSA (with respect to controls; with respect
Subjects mean 6 SD (N) respect to controls) to moderate renal impairment)
None
HSA standard, fatty acid free 66,4466114 — —
Controls 66,689697 (5) 243 (—) ,0.001 (—)
Moderate renal impairment 66,796683 (5) 350 (107) ,0.001 (.0.05; —)
ESRD 66,9446128 (3) 498 (255) ,0.001 (,0.02; .0.05)
ESRD on hemodialysis 66,884684 (5) 438 (195) ,0.001 (,0.02; .0.05)
Abbreviations are: HSA, human serum albumin; ESRD, end-stage renal disease.
DISCUSSION dized glutathione, for example [30]. There was a further
significant increase in molecular mass of HSA in patientsMass spectrometric techniques, MALDI-MS, and
with ESRD and patients with ESRD on hemodialysis.electrospray ionization mass spectrometry have been
The mean mass increments, 255 and 195 D, were notused in the study of post-translational modification of
consistent with AGE peptide-HSA adducts. They mayproteins in uremia: carbamoylation of hemoglobin, glu-
rather be due to increased AGE contents of HSA, partic-tathione adducts of lens crystallins, and AGE-modified
ularly AGE formation from glyoxal, methylglyoxal, andb2-microglobulin extracted from amyloid tissue [re- 3-deoxyglucosone, which are increased in uremia (ab-viewed in 28]. To our knowledge, this is the first study
stract; Mann et al, Kidney Int 55:2582, 1999) [31]. Incuba-of mass changes of serum albumin in uremia. There is
tion of plasma from normal controls subjects with 5 toan accumulation of AGEs in uremia [2, 11–14, 16]. Some
100 mmol/L 3-deoxyglucosone for four weeks, however,AGEs (CML, pentosidine, pyrraline, GOLD, MOLD)
did not increase the concentration of pentosidine [16],
were found in serum protein, mostly albumin [2, 11, but probably the concentration of other 3-DG–derived
12, 29], whereas other AGEs of undetermined structure AGEs (pyrraline, hydroimidazolone) were increased in
were mostly associated with AGE-modified peptides of this study. Mass increments expected on the formation
molecular mass 1500 to 2000 D [14]. These may modify of CML (58 D), pentosidine (59 D), pyrraline (108 D),
plasma proteins irreversibly [13, 20]. We therefore ex- GOLD (35 D), and MOLD (49 D) are all within this
pected to find mass increases of HSA in uremia corre- range. The small increase in molecular mass of HSA also
sponding to the modification of HSA by AGEs and indicates that HSA was modified minimally by AGEs
AGE-peptide-HSA adducts. in ESRD. The specific contents of CML, pentosidine,
MALDI-MS of all HSA in vivo samples gave signifi- pyrraline, GOLD, and MOLD of HSA in ESRD deter-
cant increases in molecular mass from that of fatty acid- mined chromatographically were also indicative of mini-
free albumin. Fatty acid removal in control samples mal modification of HSA by these AGEs in ESRD [2, 11,
decreased the molecular mass of albumin to that of au- 12, 29]. Other modifications may be involved, however:
thentic fatty acid-free HSA. Hence, the binding of fatty change of fatty acid binding to albumin or increased
acids to HSA contributes to molecular mass changes of glutathionyl-HSA disulfide formation, since oxidative
HSA in vivo. HSA also suffers other modifications in stress, as judged by changes in systemic glutathione me-
tabolism, was increased in uremia [32].vivo—mixed disulfide modification with cystine and oxi-
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Fig. 2. Specimen MALDI-MS of albumin
glycated by glucose and methylglyoxal in vitro.
(A) Human serum albumin (HSA; control),
HSA. (B) HSA minimally modified by glu-
cose-derived AGE (AGEminHSA). (C) HSA
highly modified by glucose-derived AGE
(AGE-HSA). (D) HSA minimally modified
by methylglyoxal (MGminHSA).
MALDI-MS may also be used to monitor the extent approximately 10% of protein mass. This protein has 21
lysine residues and 16 arginine residues modified by fruc-of modification of proteins glycated in vitro. The preci-
sion of the molecular mass determination of albumin tosamine and glucose-derived AGE per molecule [24].
The average mass increment per amino acid modified isderivatives with the MALDI II mass spectrometer, as
stated by the manufacturer’s specifications, is approxi- approximately 180 D and may reflect the presence of
fructosamine and AGE residues. This is a lower molecu-mately 6 133 D (0.2%). The mass increase of MGmin-
HSA, relative to unmodified HSA, was not significant lar mass than that estimated by high-performance liquid
chromatography gel filtration (81,000 D) but similar towhen determined by this technique. This was expected
since preparation of MGmin-HSA with 2-[14C]methylgly- the major band molecular mass in sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE;oxal indicated the presence of an average of 2.4 6 0.3
methylglyoxal-derived moieties per protein molecule, 73,000 D) of AGE-HSA [24], although the minor band
in SDS-PAGE at 97,000 D was not observed in MALDI-mainly modification of arginine residues as hydroimida-
zolones with a putative mass increase of approximately MS, which may be an artifact of sample preparation for
SDS-PAGE. AGE-HSA is a highly modified, glycated100 to 160 D [25]. In contrast, AGEmin-HSA had a signifi-
cant mass increment of 367 D. This is expected to reflect HSA derivative. This and similar highly modified pro-
teins have also been used in studies investigating AGEthe presence of fructosamine and AGE residues in AGEmin-
HSA. When AGEmin-HSA was prepared with 1-[14C]- receptor binding and cell activation [34, 35]. In all of
these glycated proteins, it is of interest that the molecularglucose, radiolabeling indicated the presence of an aver-
age of 1.94 6 0.15 glucose-derived moieties containing mass range was relatively narrow. Moreover, the molecu-
lar mass peaks of HSA were not broadened in MALDI-the 1-[14C] per protein molecule [25]. Similar AGE-modi-
fied proteins have been used in studies investigating MS of uremic patient samples, but rather the distribution
was shifted to slightly higher mean molecular mass inAGE receptor binding and cell activation [33]. Highly
glycated AGE-HSA had a mass increase of 6748 D or hemodialysis patients. Similar mass peak shapes were
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